Tweenvest Stocks

Kairos Pharma, Ltd. (NYSEAM: KAPA)

Health Care · Biotechnology · US

$0.23

-31.96% today · -70.9% 1Y

Kairos Pharma, Ltd. (NYSEAM: KAPA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $7.30M and employs 4 people.

Over the last twelve months the share price has lost 70.9%, trading between 0.27 and 2.11.

Tweenvest scores Kairos Pharma, Ltd. across four factors: quality 27/100. Its strongest factor is quality.

KAPA price history

Not enough price history to draw a chart yet.

Key figures

Market cap
$7.30M
Revenue (TTM)
P/E
EPS
-0.30
Dividend yield
Beta (5Y)
52-week high
$2.11
52-week low
$0.27
Avg volume (3M)
Shares outstanding
21.41M
Employees
4
Next earnings

About Kairos Pharma, Ltd.

Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer. Its therapeutic portfolio includes a range of antibodies and small molecules engineered to combat various malignancies, such as prostate, lung, and breast cancer, as well as glioblastoma. Initially incorporated in 2013 under the name NanoGB13, Inc., the enterprise officially adopted its current identity as Kairos Pharma, Ltd. in July 2016. The company's operations are headquartered in Los Angeles, California.

ISIN
US48301N1046
Founded
2013
Listed since
Sep 16, 2024
Exchange
NYSE American LLC
Currency
USD
CompanyMarket capPriceDay
AbbVie Inc.NYSE: ABBV$468.22B$264.52-0.17%
Amgen Inc.NasdaqGS: AMGN$237.52B$443.82+1.02%
Gilead Sciences, Inc.NasdaqGS: GILD$181.18B$146.72+0.41%
Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX$138.91B$547.58-0.09%
Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN$83.28B$834.55+0.06%
argenx SEENXTBR: ARGX$65.85B864.20-4.19%
Moderna, Inc.NasdaqGS: MRNA$57.92B$138.78-4.34%
CSL LimitedASX: CSL$57.77BAU$168.30-1.69%

Browse every Biotechnology company →

Figures last refreshed Aug 18, 2026.